Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trialAndrew D. Zelenetz, Franck Morschhauser, Adam M. Petrich et al.|Blood|2019Cited by 136
The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapyChristina Claus, Christian Klein|mAbs|2023Cited by 92
ME3738 protects from concanavalin A‐induced liver failure via an IL‐6‐dependent mechanismChristian Klein, Christian Trautwein|European Journal of Immunology|2003Cited by 28
The IL-6–gp130–STAT3 pathway in hepatocytes triggers liver protection in T cell–mediated liver injuryChristian Klein, Christian Trautwein|Journal of Clinical Investigation|2005Cited by 27
Prognostic significance of <i>FCGR2B</i> expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMałgorzata Nowicka, Mark S. Cragg, Laura K. Hilton et al.|Blood Advances|2021Cited by 18